NDA 209964 · Amgen INC
Corlanor
Ivabradine · Oral
Priority reviewOrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Aug 4, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Apr 22, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
95
23 Phase 3, 5 recruiting
FAERS reports
6,950
5,003 serious, 532 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 9, 2026.
1. INDICATIONS AND USAGE Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 ) For the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients ages 6 months and older. ( 1.2 ) 1.1 Heart Failure in Adult Patients Corlanor is indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use. 1.2 Heart Failure in Pediatric Patients Corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate.
Mechanism: Corlanor blocks the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel responsible for the cardiac pacemaker I f current, which regulates heart rate. In clinical electrophysiology studies, the cardiac effects were most pronounced in the sinoatrial (SA) node, but prolongation of the AH interval has occurred as has PR interval prolongation. There was no effect on ventricular repolarization and no effects on myocardial contractility [see Clinical Pharmacology ( 12.2 )] . Corlanor can also inhibit the retinal current I h . I h is involved in curtailing retinal responses to bright...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 22, 2019 Original approval · Type 3 - New Dosage Form · priority review OrphanLabelMedication GuideLetter
1 products under this application
- CORLANOR · IVABRADINE 5MG/5ML (1MG/ML) · SOLUTION, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Ivabradine" as an intervention, any sponsor and status, largest first.
- Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart FailurePivotal-lookingCompleted
Institut de Recherches Internationales ServierAcademic, hospital or other
NCT02446990 · 19,102 participants · Start Sep 2009 · Primary completion Jan 2014
Drug: Ivabradine; Placebo · For: Coronary Artery Disease
Sites: Ferrara, Italy; London, United Kingdom
- The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic DysfunctionPivotal-lookingCompleted
Institut de Recherches Internationales ServierAcademic, hospital or other
NCT00143507 · 10,917 participants · Start Dec 2004 · Primary completion Feb 2008
Drug: Ivabradine; Placebo · For: Coronary Disease; Ventricular Dysfunction, Left
Sites: London, United Kingdom
- Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre StudyPivotal-lookingCompleted
Institut de Recherches Internationales ServierAcademic, hospital or other
NCT02441218 · 6,505 participants · Start Sep 2006 · Primary completion Apr 2010
Drug: Ivabradine; Placebo · For: Chronic Heart Failure
Sites: Paris, France; Gothenburg, Sweden
- Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery Trial (PREVENT-MINS)Pivotal-lookingActive, not recruiting
Jagiellonian UniversityAcademic, hospital or other
NCT05279651 · 2,146 participants · Start Jun 13, 2022 · Primary completion Apr 30, 2025
Drug: Ivabradine; Placebo · For: Myocardial Injury After Noncardiac Surgery (MINS); Myocardial Ischemia
Sites: Bydgoszcz, Poland; Ciechanów, Poland; Cieszyn, Poland · 26 sites in all
- Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina PectorisPivotal-lookingCompleted
Institut de Recherches Internationales ServierAcademic, hospital or other
NCT00202566 · 750 participants (planned) · Start Jun 2005
Drug: Ivabradine · For: Angina Pectoris
Sites: Montreal, Canada
- Ivabradine for Heart Rate Control In Septic ShockPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT04031573 · 429 participants · Start Feb 26, 2021 · Primary completion Feb 19, 2026
Drug: Ivabradine; Ivabradine and 1 more · For: Septic Shock
Sites: Créteil, France
- The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral RegurgitationPivotal-lookingStatus unknown
Kaohsiung Veterans General Hospital.Academic, hospital or other
NCT04217135 · 400 participants (planned) · Start Jan 1, 2017 · Primary completion Jul 31, 2022
Drug: evidence-based medications vs. high-dose hydralazine + evidence-based medications · For: Systolic Heart Failure Stage D (Disorder); Mitral Regurgitation
Sites: Kaohsiung City, Taiwan
- RECOVER-AUTONOMIC Platform ProtocolPivotal-lookingCompleted
Kanecia Obie ZimmermanAcademic, hospital or other
NCT06305780 · 381 participants · Start Mar 11, 2024 · Primary completion Jul 9, 2025
Drug: IVIG + Coordinated Care; IVIG Placebo + Coordinated Care and 6 more · For: Long COVID; Long Covid19; Long Covid-19
Sites: Opelika, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 50 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,369
- dyspnoea478
- hypotension450
- dizziness366
- cardiac failure347
- fatigue342
- drug interaction332
- drug ineffective302
- nausea276
- bradycardia258
- headache251
- chest pain206
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 5 |
| 2009 | 6 |
| 2010 | 11 |
| 2011 | 21 |
| 2012 | 42 |
| 2013 | 55 |
| 2014 | 105 |
| 2015 | 336 |
| 2016 | 683 |
| 2017 | 603 |
| 2018 | 582 |
| 2019 | 546 |
| 2020 | 610 |
| 2021 | 574 |
| 2022 | 663 |
| 2023 | 529 |
| 2024 | 575 |
| 2025 | 610 |
| 2026 | 393 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Mar 24, 2026
Corlanor, Solution, 5 mg/5 mL (NDC 55513-813-28). Discontinuation of the manufacture of the drug product
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Corlanor (IVabradine HCl)
2024 spending
$40.0M
Beneficiaries
12,631
50,208 claims
Per beneficiary
$3,164
$9.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $26,465,187 |
| 2021 | $31,260,406 |
| 2022 | $38,416,173 |
| 2023 | $47,305,472 |
| 2024 | $39,961,291 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction.
Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. · JACC Heart Fail 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Interactions between herbal medicines and prescribed drugs: an updated systematic review.
Izzo AA, Ernst E · Drugs 2009 · Systematic Review
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Swedberg K, Komajda M, Böhm M, et al. · Lancet 2010 · Multicenter Study, Randomized Controlled Trial
- Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome.
Taub PR, Zadourian A, Lo HC, et al. · J Am Coll Cardiol 2021 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Systematic literature review: treatment of postural orthostatic tachycardia syndrome (POTS).
Schiweck N, Langer K, Maier A, et al. · Clin Auton Res 2026 · Systematic Review
- The evidence for treatments for postural orthostatic tachycardia syndrome: a systematic review of randomized trials.
Kwok CS, Lee S, Hall M, et al. · Trends Cardiovasc Med 2025 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Amgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.